Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Cancer

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/ijc.29483PMID 25688715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.

  2014cited by this paper
• High‐throughput SNP‐based authentication of human cell lines

  2013cited by this paper
• Analysis of the Clinical characteristics of Nasal vestibule Masses

  2013cited by this paper
• Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

  2013cited by this paper
• Integration of Different “-omics” Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells

  2013cited by this paper
• Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

  2013cited by this paper
• Shikonin Kills Glioma Cells through Necroptosis Mediated by RIP-1

  2013cited by this paper
• Gene expression changes associated with erlotinib response in glioma cell lines.

  2013cited by this paper
• Personalized medicine for glioblastoma: current challenges and future opportunities.

  2013cited by this paper
• Advances and challenges in the treatment of glioblastoma: a clinician's perspective.

  2013cited by this paper
• Targeting EGFR and PI3K pathways in ovarian cancer

  2012cited by this paper
• Antimicrobial and Cytotoxic Isohexenylnaphthazarins from Arnebia euchroma (Royle) Jonst. (Boraginaceae) Callus and Cell Suspension Culture

  2012cited by this paper
• Novel Multiple Apoptotic Mechanism of Shikonin in Human Glioma Cells

  2012cited by this paper
• Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

  2012cited by this paper
• Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

  2012cited by this paper
• Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells

  2012cited by this paper
• Natural products as sources of new drugs over the 30 years from 1981 to 2010.

  2012cited by this paper
• Naphthoquinones from Onosma paniculata Induce Cell-Cycle Arrest and Apoptosis in Melanoma Cells

  2012cited by this paper
• Nec-1 Enhances Shikonin-Induced Apoptosis in Leukemia Cells by Inhibition of RIP-1 and ERK1/2

  2012cited by this paper
• Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.

  2011cited by this paper
• Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia

  2011cited by this paper
• Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines

  2010cited by this paper
• Natural products derived from traditional chinese medicine as novel inhibitors of the epidermal growth factor receptor.

  2010cited by this paper
• Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

  2010cited by this paper
• The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.

  2010cited by this paper
• Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

  2009influential reference
• The EGFRvIII variant in glioblastoma multiforme.

  2009cited by this paper
• Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

  2009cited by this paper
• Targeting the EGFR and the PKB pathway in cancer.

  2009cited by this paper
• Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

  2009cited by this paper
• Tumor Dependence on the EGFR Signaling Pathway Expressed by the p-EGFR:p-AKT Ratio Predicts Erlotinib Sensitivity in Human Non-small Cell Lung Cancer (NSCLC) Cells Expressing Wild-Type EGFR Gene

  2008cited by this paper
• Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.

  2008cited by this paper
• Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

  2008cited by this paper
• Faculty Opinions recommendation of Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.

  2007cited by this paper
• Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• A new EGFR inhibitor induces apoptosis in colon cancer cells.

  2007cited by this paper
• Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy

  2007cited by this paper
• Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface

  2007cited by this paper
• Natural products as sources of new drugs over the last 25 years.

  2007cited by this paper
• Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors

  2006influential reference
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Oncogenic growth factor receptors: implications for signal transduction therapy.

  2004cited by this paper
• Systematic discovery of multicomponent therapeutics

  2003cited by this paper
• Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells.

  2003cited by this paper
• A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases.

  2003cited by this paper
• Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide

  2003cited by this paper
• Shikonin derivatives: synthesis and inhibition of human telomerase.

  2002cited by this paper
• β‐Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases

  2002cited by this paper
• Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.

  2001cited by this paper
• Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I.

  1995cited by this paper
• Comments on the isobole method for analysis of drug interactions.

  1992cited by this paper

• A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules

  2025cites this paper
• Shikonin a potent phytotherapeutic: a comprehensive review on metabolic reprogramming to overcome drug resistance in cancer

  2025cites this paper
• Shikonin inhibits epithelial-mesenchymal transition in glioblastoma cells by upregulating p53 and promoting miR-361-5p level to suppress ZEB1 expression

  2025cites this paper
• A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

  2024cites this paper
• Regulated cell death in glioma: promising targets for natural small-molecule compounds

  2024cites this paper
• The Anti-tumor Function of Shikonin by Targeting EGFR/AKT/mTOR Signaling in Human Osteosarcoma Cells

  2024cites this paper
• Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2

  2024cites this paper
• Unveiling the Potentiality of Shikonin Derivatives Inhibiting SARS-CoV-2 Main Protease by Molecular Dynamic Simulation Studies

  2023cites this paper
• Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways

  2023cites this paper
• Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.

  2023cites this paper
• Discovery of a heat-generated compound DHD derived from Patrinia villosa water extract with inhibitory effects on colon cancer cells viability and migration

  2023cites this paper
• Temozolomide, Simvastatin and Acetylshikonin Combination Induces Mitochondrial-Dependent Apoptosis in GBM Cells, Which Is Regulated by Autophagy

  2023cites this paper
• Comparative Analysis of Shikonin and Alkannin Acyltransferases Reveals Their Functional Conservation in Boraginaceae.

  2023cites this paper
• Shikonin derivatives cause apoptosis and cell cycle arrest in human chondrosarcoma cells via death receptors and MAPK regulation

  2022cites this paper
• Therapeutics for Chemotherapy-Induced Peripheral Neuropathy: Approaches with Natural Compounds from Traditional Eastern Medicine

  2022cites this paper
• Deoxyshikonin Mediates Heme Oxygenase-1 Induction and Apoptotic Response via p38 Signaling in Tongue Cancer Cell Lines

  2022cites this paper
• The role of shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.

  2022cites this paper
• Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling

  2022cites this paper
• Associations of Gut Microbiota and Fatty Metabolism With Immune Thrombocytopenia

  2022cites this paper
• Shikonin Derivatives Inhibit Inflammation Processes and Modulate MAPK Signaling in Human Healthy and Osteoarthritis Chondrocytes

  2022cites this paper
• In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors

  2022cites this paper
• Transcriptomics, molecular docking, and cross-resistance profiling of nobiletin in cancer cells and synergistic interaction with doxorubicin upon SOX5 transfection.

  2022cites this paper
• Screening and characterization estrogen receptor ligands from Arnebia euchroma (Royle) Johnst. via affinity ultrafiltration LC-MS and molecular docking

  2022cites this paper
• Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from Lithospermum erythrorhizon Sieb. et Zucc

  2022cites this paper
• Polish Achievements in Bioactive Compound Production From In Vitro Plant Cultures

  2022cites this paper
• Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).

  2022cites this paper
• Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis

  2021cites this paper
• Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.

  2021cites this paper
• Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment.

  2021cites this paper
• Anti-cancer Research on Arnebiae Radix-derived Naphthoquinone in Recent Five Years.

  2021cites this paper
• Targeting Drug Chemo-Resistance in Cancer Using Natural Products

  2021cites this paper
• The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma

  2021cites this paper
• RIPK3 signaling and its role in the pathogenesis of cancers

  2021cites this paper
• Drug penetration through the blood–brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance

  2021cites this paper
• Synthesis and Pharmacological In Vitro Investigations of Novel Shikonin Derivatives with a Special Focus on Cyclopropane Bearing Derivatives

  2021cites this paper
• Cytotoxicity of apigenin toward multiple myeloma cell lines and suppression of iNOS and COX-2 expression in STAT1-transfected HEK293 cells.

  2020cites this paper
• Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis

  2020cites this paper
• Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2

  2020cites this paper
• Cancer Chemopreventive Potential of Epidermal Growth Factor Receptor Inhibitors from Natural Products

  2020cites this paper
• Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

  2020cites this paper
• Two new dimeric naphthoquinones from Arnebia euchroma

  2020cites this paper
• Deoxyshikonin inhibits cisplatin resistance of non–small‐cell lung cancer cells by repressing Akt‐mediated ABCB1 expression and function

  2020cites this paper
• Induction of Apoptosis, Autophagy and Ferroptosis by Thymus vulgaris and Arctium lappa Extract in Leukemia and Multiple Myeloma Cell Lines

  2020cites this paper
• An improved and practical synthesis route to antiproliferative (±)-shikonin and its O-acyl derivatives

  2020cites this paper
• Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology.

  2019cites this paper
• Shikonin potentiates paclitaxel antitumor efficacy in esophageal cancer cells via the apoptotic pathway

  2019cites this paper
• The diverse mechanisms and anticancer potential of naphthoquinones

  2019cites this paper
• Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases

  2019cites this paper
• Shikonin derivatives for cancer prevention and therapy.

  2019cites this paper
• Collateral Sensitivity of Parthenolide via NF-κB and HIF-α Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines

  2019cites this paper
• Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.

  2019cites this paper
• Synthesis, biological function and evaluation of Shikonin in cancer therapy.

  2019cites this paper
• Collateral sensitivity of natural products in drug-resistant cancer cells.

  2019cites this paper
• Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.

  2019cites this paper
• Molecular identification and phytochemical screening of endophytic fungi isolated from Lithospermum officinale L. roots: A new source of shikonin.

  2019cites this paper
• Shikonin enhances sensitization of gefitinib against wild‐type EGFR non‐small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway

  2018cites this paper
• Using drugs to target necroptosis: dual roles in disease therapy.

  2018cites this paper
• Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy

  2018cites this paper
• Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin

  2018cites this paper
• Molecular Determinants of Sensitivity or Resistance of Cancer Cells Toward Sanguinarine

  2018cites this paper
• Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects

  2018cites this paper
• Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells

  2018cites this paper
• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

  2018cites this paper
• SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer

  2017cites this paper
• Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells

  2017influential citation
• Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells

  2017influential citation
• Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition

  2017cites this paper
• Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c‐Met‐Mediated Epithelial‐to‐Mesenchymal Transition

  2017cites this paper
• Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?

  2016cites this paper
• Anticancer , Antimicrobial and other Pharmacological Properties of Shikonin and its Derivatives

  2016cites this paper
• Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species

  2016cites this paper
• β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.

  2016cites this paper
• Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells

  2015cites this paper
• Systematic identification of shikonins and shikonofurans in medicinal Zicao species using ultra-high performance liquid chromatography quadrupole time of flight tandem mass spectrometry combined with a data mining strategy.

  2015cites this paper
• Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells

  2015cites this paper